Giampaolo Bianchini

Giampaolo Bianchini
تخصص :
مهنة :
طبيب الأورام
اللغات :
EN
IT

هل تحتاج الى موعد؟

اتصل بنا وسنعتني بك.
Secure your spot with the doctor
View doctor availability
Send request

السيرة الذاتية

Professor Giampaolo Bianchini is Head of Breast Oncology within the Department of Medical Oncology at IRCCS Ospedale San Raffaele and Associate Professor at the Vita-Salute San Raffaele University.

After graduating in Medicine and Surgery in 2000 from the University of Milano-Bicocca, he specialized in Medical Oncology in 2004 at the University of Milan.

During his training, he carried out Visiting Scientist activities at several prestigious American institutions, including the National Cancer Institute (Bethesda), the MD Anderson Cancer Center (Houston), and the Yale Cancer Center (New Haven).

Professor Bianchini treats patients with both early-stage and metastatic breast cancer and has nearly twenty-five years of clinical experience. He is internationally recognized as an opinion leader in the field of breast cancer. He also has a strong interest in the development of new therapies and immunotherapy approaches for the treatment of this disease.

Professor Bianchini is also Head of the Translational Clinical Research and Immunotherapy Group within the Department of Medical Oncology, and he is involved in numerous research projects dedicated to women with breast cancer, aimed at understanding mechanisms of drug response and resistance, identifying new therapeutic strategies, and defining biomarkers that improve treatment personalization.

He is the author of numerous publications in international journals such as Nature, The Lancet, Annals of Oncology, The Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, Nature Reviews Clinical Oncology and many others. He regularly participates in national and international conferences and congresses.

اقرأ المزيدأقرأ أقل

التعليم

University of Milan Bicocca
Degree in Medicine and Surgery - 2000

University of Milan Bicocca
Medical Oncology Specialization - 2004

معرض الوسائط المتعددة

المنشورات

Dr. Bianchini is the author of numerous publications in international journals such as the Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Journal National Cancer Institute, JAMA Oncology and Annals of Oncology. Its H index is 22. He regularly participates in national and international congresses and symposia.

أحدث المنشورات

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
J Clin Oncol 28:4316-23, 2010
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Cancer Res 70:8852-62, 2010
Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang C, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WK, Gianni L, Pusztai L.
قراءة المزيد
Biological processes associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
J Natl Cancer Inst 2010 Dec 29
Iwamoto T, Bianchini G, Booser D, QI Y, Coutant C, Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes F, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai
قراءة المزيد
Breast cancer genomics: challenges in interpretation and application.
Oncologist. 2013;18(4):e11-2
Kelly CM, Symmans WF, Andreopoulou E, Bianchini G
قراءة المزيد
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Breast Cancer Research 2013 15:R86
Bianchini G*, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Muller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Angelica F, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
قراءة المزيد
An unmeet need: tailoring extended adjuvant endocrine therapy
British Journal of Cancer (2013), 1–4
Bianchini G, Gianni L
قراءة المزيد
The immune system and response to her2-targeted therapy in breast cancer.
The Lancet Oncology (2014) 15:e58-e68
Bianchini G, Gianni L
قراءة المزيد
Research-based pam50 subtype predictor identifies higher responses and improved survival outcomes in her2-positive breast cancer in the noah study.
Clin Cancer Res (2014) 20:511-21, 2014
Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez V, Gianni L, Baselga J
قراءة المزيد
Immune modulation of pathologic complete response after neoadjuvant her2-directed therapies in the neosphere trial.
Annals of Oncology 26(12): 2429-36
Bianchini G, Pusztai L, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Galeota E, Magazzù D, Rodríguez J, Oh D-Y, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L
قراءة المزيد
Subtype specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer.
Clinical Cancer Research 22(2): 337-45
Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G*
قراءة المزيد
New strategies in breast cancer: immunotherapy.
Clin Cancer Res 22(9): 2105-10
Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G
قراءة المزيد
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Nat Rev Clin Oncol Nov;13(11):674-690.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L
قراءة المزيد
Biomarker analysis of the neosphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of her2-positive breast cancer.
Breast Cancer Res 19(1): 16
Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L
قراءة المزيد
Association between genomic metrics and immune infiltration in triple-negative breast cancer.
JAMA Oncology (doi:10.1001/jamaoncol.2017.2140)
Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L
قراءة المزيد
Is trastuzumab single agent obsolete in eraly breast cancer? No.
Breast. 2019 Feb;43:142-145
Bianchini G
قراءة المزيد